Citius Pharmaceuticals (CTXR) to Post Earnings on Tuesday

Citius Pharmaceuticals (NASDAQ:CTXR) is projected to announce its Q3 2026 results before the market opens on Tuesday, August 11th. Analysts expect Citius Pharmaceuticals to post earnings of ($0.36) per share and revenue of $5.4590 million for the quarter. Individuals may visit the the company’s upcoming Q3 2026 earning overview page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Citius Pharmaceuticals (NASDAQ:CTXR) last issued its earnings results on Friday, May 15th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.67). On average, analysts expect Citius Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Citius Pharmaceuticals Price Performance

CTXR traded up $0.02 during mid-day trading on Tuesday, hitting $0.62. The stock had a trading volume of 67,671 shares, compared to its average volume of 565,418. The stock’s fifty day simple moving average is $0.57 and its 200-day simple moving average is $0.70. The firm has a market capitalization of $16.96 million, a price-to-earnings ratio of -0.29 and a beta of 1.03. Citius Pharmaceuticals has a 1-year low of $0.47 and a 1-year high of $2.19.

Institutional Trading of Citius Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. XTX Topco Ltd bought a new stake in Citius Pharmaceuticals during the 2nd quarter worth about $32,000. NewEdge Advisors LLC bought a new position in shares of Citius Pharmaceuticals in the 2nd quarter valued at about $40,000. Asset Advisory Group Inc. acquired a new stake in shares of Citius Pharmaceuticals in the fourth quarter valued at about $46,000. Finally, Heights Capital Management Inc. acquired a new stake in shares of Citius Pharmaceuticals in the fourth quarter valued at about $622,000. 16.88% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Zacks Research upgraded shares of Citius Pharmaceuticals to a “hold” rating in a research report on Tuesday, May 19th. Wall Street Zen lowered Citius Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, June 6th. Weiss Ratings reissued a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research note on Wednesday, June 24th. Finally, HC Wainwright restated a “buy” rating and issued a $4.00 price target on shares of Citius Pharmaceuticals in a report on Monday, May 18th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $5.00.

About Citius Pharmaceuticals

Citius Pharmaceuticals is a clinical?stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital?acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter?related bloodstream infections without catheter removal.